MedTrace Logo

Effects of the Örebro Prevention Program on Youth Drinking

NCT01213108 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1752

Last updated 2010-10-01

No results posted yet for this study

Summary

The Örebro prevention program is a brief (6 x 30 minutes)program administered to parents of 13-16 year old youths in regular parental meetings. The program aims to encourage parents to maintain a restrictive attitude towards youth drinking throughout their children's teenage years, and thereby postpone and reduce youth drinking. A previous quasi-experimental study by the program developers showed a sustained alcohol-specific restrictivity among parents exposed to the program, and also a reduction on drinking measures among the youths of the exposed parents (Koutakis, Stattin \& Kerr, 2008). This study aims to investigate whether these effects are sustained also when the program has gone into wide dissemination in Sweden.

Conditions

  • Youth Drinking

Interventions

BEHAVIORAL

Örebro prevention program

6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth

BEHAVIORAL

Business as usual

Regular alcohol prevention activities and curricula in Swedish schools

Sponsors & Collaborators

  • Swedish National Institute of Public Health

    collaborator UNKNOWN

  • Alcohol Research Council of the Swedish Alcohol Retailing Monopoly

    collaborator UNKNOWN

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Maria C Bodin, PhD · Centre for Psychiatry Research Stockholm, Karolinska Institutet/Stockholm County Council Health Care Provision

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213108 on ClinicalTrials.gov